BridgeBio Pharma (NASDAQ:BBIO) and Maze Therapeutics recently announced the formation of a partnership, Contour Therapeutics, to transform and advance innovative approaches to precision medicine for the treatment of cardiovascular disease, which is one of biggest cause for deaths globally.
This joint venture between two leading biotech companies unites Maze‘s genetically powered approach to drug discovery with the experience of BridgeBio in cardiac drug discovery and clinical development, as well as insights from its COMPASS network.
Together the companies will concentrate on advancing, through clinical research, genetically validated therapeutic candidates and will initially work on the development of medication for patients with undisclosed, genetically specified types of heart failure.
The latest collaboration relies on exciting progress in the detection and targeting of genetic causes of cardiovascular diseases, such as the precise medicine strategy of BridgeBio at its affiliate Eidos Therapeutics for the treatment of transthyretin amyloidosis, an under-diagnosed and life-threatening cause of heart failure.
The partnership also focuses on seminal innovations in the treatment of hereditary cardiomyopathies, like MyoKardia, a company co-founded by BridgeBio and Maze senior executives.
BridgeBio Pharma (NASDAQ:BBIO) Stock went up by 1.91% from its latest closing price in pre market today. BBIO stock went up by 5.59% for the week, with a monthly jump of 34.86% and a quarterly performance of 83.61%